Market News & Trends
Xequel Bio Announces Positive Results From Phase 1b Study for Novel aCT1 Ophthalmic Solution
Xequel Bio, Inc. recently announced positive results from its Phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in…
US Alliance Pharma Acquires UK-Based LGC’s Drug Development Solutions Business
Alliance Pharma recently closed on the purchase of Drug Development Solutions (DDS) from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc., a leading global investment….
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient
Comera Life Sciences Holdings, Inc. recently announced favorable topline results from its recently completed SEQURUS-1 study. The results of this preclinical study provide supportive evidence…
Evonik Now Offers Enteric-Protected Ready-to-Fill Capsules – EUDRACAP- in IPEC-GMP Quality
Evonik’s EUDRACAP enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP enteric are….
Roquette Expands PEARLITOL SD Mannitol Range for Highly Sensitive APIs
Roquette recently announced the addition of a new grade to its PEARLITOL SD mannitol range for direct compression – PEARLITOL 150 SD. Developed specifically for….
ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses
ABL recently announced its partnership with KaliVir Immunotherapeutics in which ABL will manufacture KaliVir’s oncolytic viruses for its….
Gerresheimer Awarded EcoVadis Gold for Sustainable Corporate Management for the First Time
Gerresheimer has been awarded the gold medal for the first time by EcoVadis, one of the leading providers of sustainability rankings, for the successful implementation…
Agarose Bead Technologies Triples its Production Capacity With Major Manufacturing Expansion
Agarose Bead Technologies (ABT) plans a major expansion of its manufacturing capabilities, tripling its production capacity to meet the global demand for agarose resins. With…
Immunocore Announces Dosing of First Patient With ImmTAV Bispecific for HIV
Immunocore Holdings plc recently announced the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific…
MediWound Announces Positive Initial Data From Phase 1/2 Study for the Treatment of Basal Cell Carcinoma
MediWound Ltd. recently announced positive initial data from 11 patients in its ongoing open-label Phase 1/2 study of MW005 for the treatment of low-risk Basal…
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Acer Therapeutics & Relief Therapeutics Announce China National Intellectual Property Administration Issued Utility Model Patent
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the China National Intellectual Property Administration (CNIPA) issued Electronic Patent Certificate ZL202122004991.9 on May…
Sirio Pharma Announces Agreement to Acquire Best Formulations
Sirio Pharma Co., Ltd. – the global nutraceutical contract development and manufacturing organization (CDMO) – and Best Formulations, Inc. recently announced that they have entered…
Absci Enters Multi-Program Collaboration With Emerging Biotech Partner
Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial
Akari Therapeutics, Plc recently announced a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase 3 Part A clinical trial in pediatric hematopoietic stem….
Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine
Insilico Medicine recently announced the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary AI-driven target discovery engine….
Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea
Alvotech recently announced the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea…..
PDS Biotech Announces Efficacy & Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head & Neck Cancer
PDS Biotechnology Corporation recently announced a poster presentation of preliminary data from its ongoing Phase 2 VERSATILE-002 clinical trial at the American Society of Clinical…
VectorBuilder to Invest $30 million to Build the World’s First AAV Superbank
VectorBuilder Inc. recently announced its plan to invest $30 million to build an AAV Superbank for the research and drug discovery community. The company will…
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Immutep Limited recently announced the grant of a new patent (number 7074341) titled Anti-LAG-3 Antibodies by the Japanese Patent Office. This new Japanese patent follows…